Evidence map›Paper›PMID 42098481›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026

Prospective study assessing the feasibility of hippocampal-sparing radiotherapy in lung cancer patients requiring cranial irradiation.

Divya Khosla, Treshita Dey, Gaurav Trivedi, Rakesh Kapoor, Navneet Singh, Vaishali Kataria, Aditya Kumar Singla, Renu Madan, Shikha Goyal, Arun Singh Oinam and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Divya KhoslaDept. of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. dr_divya_khosla@yahoo.com.
Treshita DeyDept. of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Gaurav TrivediDept. of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Rakesh KapoorDept. of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Navneet SinghDept. of Pulmonary Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Vaishali KatariaDept. of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Aditya Kumar SinglaDept. of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Renu MadanDept. of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Shikha GoyalDept. of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Arun Singh OinamDept. of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Aditya MehtaDept. of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Akhilesh SharmaDept. of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Kannan PeriasamyDept. of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLung cancer remains one of the leading causes of cancer-related mortality worldwide, with systemic therapies often limited by poor intracranial penetration, resulting in frequent brain relapses. Whole-brain radiotherapy (WBRT) plays a central role in managing brain metastases and in prophylaxis, although it is frequently associated with significant neurocognitive decline. Hippocampal-sparing WBRT (HSWBRT) represents a strategy to preserve neurocognition and quality of life (QoL) while maintaining disease control. This study evaluated the feasibility and outcomes of HSWBRT in lung cancer patients requiring prophylactic cranial irradiation (PCI) or WBRT.

methodsIn this prospective study (2021-2023), 15 patients with histologically confirmed lung cancer with an indication for PCI or WBRT (lesions > 5 mm from hippocampus) were treated with HSWBRT. Target delineation followed Radiation Therapy Oncology Group (RTOG) guidelines, incorporating a 5-mm isotropic margin for hippocampal avoidance. Prescribed doses were 25 Gy in 10 fractions for PCI and 30 Gy in 10 fractions for brain metastases. Neurocognitive function was assessed using the Montreal Cognitive Assessment (MOCA), Trail Making Test parts A and B (Trail A/B), and the Controlled Oral Word Association Test (COWAT). Quality of life was evaluated with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and EORTC Brain Cancer Module (BN20) at baseline and at 2, 4, 6, 9, and 12 months. Outcomes were compared with a retrospective cohort of 15 patients treated with conventional WBRT. The Kaplan-Meier method was used for survival analysis; comparisons employed log-rank and repeated measures analysis of variance tests.

resultsMedian follow-up was 20 months. Intracranial relapse and overall survival rates did not differ significantly between the HSWBRT and WBRT arms. However, self-reported cognitive decline and QoL deterioration were lower in the HSWBRT arm at 12 months (QoL: 83.33 vs. 66.67, p = 0.07). The MOCA scores remained stable, and Trail A/B performance improved post-treatment in the HSWBRT cohort.

conclusionOur findings show that HSWBRT appears feasible and effective in preserving neurocognitive function and QoL in lung cancer patients, without compromising intracranial control. Larger randomized studies are needed to validate its role in routine practice.

Indexed as

Hippocampus sparing whole brain radiotherapyLung cancerNeurocognitive declineQuality of lifeWhole brain radiotherapy

Identifiers

PMID42098481

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.